Evidence map›Paper›PMID 19272817›Full record

ArticleOral surgery, oral medicine, oral pathology, oral radiology, and endodontics2009

Immunohistochemical expression of the oncogenic molecules active Stat3 and survivin in benign and malignant salivary gland tumors.

Nikolaos G Nikitakis, Mark A Scheper, Vasileios S Papanikolaou, Alexandra Sklavounou, John J Sauk

Abstract read
In one paragraph

Article in Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. The sonic hedgehog signaling pathway contributes to the development of salivary gland neoplasms regardless of perineural infiltration.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Nikolaos G NikitakisDepartment of Oral Pathology and Medicine, School of Dentistry, National and Kapodistrian University of Athens, Athens, Greece. nnikitakis1@yahoo.com
Mark A Scheper
Vasileios S Papanikolaou
Alexandra Sklavounou
John J Sauk
National and Kapodistrian University of Athens · GRUniversity of Louisville · USUniversity of Louisville Hospital · USUniversity of Maryland, Baltimore · US

Funding

NOVEL SERPIN INHIBITOR OF ORAL SQUAMOUS CARCINOMAR01DE012606 · NIDCR · UNIVERSITY OF MARYLAND BALTIMORE · PI ORD, ROBERT · 1999 to 2007
$2.1M
CELL SURFACE MARKER AND HOMING TARGET FOR ORAL SCCR01DE013118 · NIDCR · UNIVERSITY OF MARYLAND BALTIMORE · PI SAUK, JOHN J · 2000 to 2003
$1.2M
NIDCR NIH HHS DE12606NIDCR NIH HHS DE13118NIDCR NIH HHS R01 DE012606NIDCR NIH HHS R01 DE013118
6 · The paper itself

Abstract

objectiveSignal transducer and activator of transcription 3 (Stat3) and survivin have been shown to exert oncogenic effects in various human neoplasms. The purpose of this study was to evaluate the expression of tyrosine phosphorylated (active) Stat3 and survivin in various benign and malignant salivary gland tumors (SGTs). STUDY

designEighty-six SGTs (65 malignant and 21 benign tumors of various histopathologic subtypes) were immunohistochemically stained with antisurvivin or anti-phosphorylated tyrosine-705 (p-tyr) Stat3 antibodies. Immunohistochemical reactivity was graded in a semiquantitative manner; a combined score of immunohistochemical positivity (0-6) was calculated for each tumor by adding the individual scores for percentage of tumor cells (0-3) and intensity of staining (0-3).

resultsSurvivin was immunohistochemically detected in all studied benign and malignant SGTs; p-tyr Stat3 was also detected in the majority (91%) of SGTs. The average combined scores for survivin and p-tyr Stat3 immunohistochemical expression in the studied malignant SGTs was 4.40 and 3.35, respectively; the corresponding combined scores for survivin and p-tyr Stat3 in the studied benign SGTs were 4.37 and 3.22, respectively. No statistically significant differences (P > .05) in p-tyr Stat3 or survivin expression were detected between the benign and malignant groups, or among the various examined histopathologic subtypes of SGTs. In contrast, normal salivary gland tissues revealed only weak and focal survivin or p-tyr Stat3 immunoreactivity, mainly localized to ductal and mucous cells.

conclusionsOur data indicate an almost universal expression of activated Stat3 and survivin in benign and malignant SGTs. Considering the well established proliferative and antiapoptotic properties of these molecules and their functional interrelationship, selective targeting techniques against Stat3 and/or survivin may represent promising therapeutic strategies against neoplasms of salivary gland origin.

Indexed as

CarcinomaHumansImmunohistochemistryInhibitor of Apoptosis ProteinsMicrotubule-Associated ProteinsPhosphorylationSalivary Gland DiseasesSalivary Gland NeoplasmsSignal TransductionSTAT3 Transcription FactorSurvivinTissue DistributionBIRC5 protein, humanInhibitor of Apoptosis ProteinsMicrotubule-Associated ProteinsSTAT3 Transcription FactorSurvivin

Identifiers

PMID19272817
PMCPMC4287356
OpenAlexW2070929589

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.